Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 911

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

Open access
Marotta, Lauren L.C., Almendro, Vanessa, Marusyk, Andriy, Shipitsin, Michail, Schemme, Janina, Walker, Sarah R., Bloushtain-Qimron, Noga, Kim, Jessica J., Choudhury, Sibgat A., Maruyama, Reo, Wu, Zhenhua, Gönen, Mithat, Mulvey, Laura A., Bessarabova, Marina O., Huh, Sung Jin, Silver, Serena J., Kim, So Young, Park, So Yeon, Lee, Hee Eun, Anderson, Karen S., Richardson, Andrea L., Nikolskaya, Tatiana, Nikolsky, Yuri, Liu, X. Shirley, Root, David E., Hahn, William C., Frank, David A., Polyak, Kornelia·2011·Journal of Clinical Investigation

Abstract

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression. We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24- cells that have stem cell-like characteristics, and CD44-CD24+ cells that resemble more differentiated breast cancer cells. Here we identified 15 genes required for cell growth or proliferation in CD44+CD24- human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation. We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24- breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their number and blocked growth of xenografts. Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci44745

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 911

Metadata

Authors
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., Wu, Z., Gönen, M., Mulvey, L. A., Bessarabova, M. O., Huh, S. J., Silver, S. J., Kim, S. Y., Park, S. Y., Lee, H. E., Anderson, K. S., Richardson, A. L., Nikolskaya, T., Nikolsky, Y., Liu, X. S., Root, D. E., Hahn, W. C., Frank, D. A., & Polyak, K.
Venue
Journal of Clinical Investigation
Published
2011-07-01
Volume
121
Issue
7
Pages
2723-2735
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2153086428
Cited by
911
References
5
FWCI
27.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. https://app.cochat.ai/papers/10.1172/jci44745
The paper
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., Wu, Z., Gönen, M., Mulvey, L. A., Bessarabova, M. O., Huh, S. J., Silver, S. J., Kim, S. Y., Park, S. Y., Lee, H. E., . . . Polyak, K. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. Journal of Clinical Investigation. https://doi.org/10.1172/jci44745

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.